Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2006

01.11.2006 | Original Paper

The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness

verfasst von: Yan Zhang, Mei-Yu Hu, Wei-Zhong Wu, Zhi-Jun Wang, Kang Zhou, Xi-Liang Zha, Kang-Da Liu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The change of cell mobility is one of the preconditions of tumor metastasis. Cell skeleton alteration and rearrangement of F-actin was closely related to cell mobility. Ezrin is a membrane-cytoskeleton organizer that can mediate the rearrangement and the function of F-actin. In this paper, we investigated the effect of ezrin on hepatocellullar carcinoma cell growth and invasiveness.

Methods

Hepatocellular carcinoma cell lines such as MHCC-1, MHCC97-H, SF7721, SMMC7721, Hep3B, and HepG2 were chosen in this study. We first examined the expression and the distribution of ezrin and F-actin in these cell lines using immunofluorescence, RT–PCR, and the western blot. Next we used small interfering RNA (siRNA) to down-regulate ezrin expression in MHCC-1, MHCC97-H, SF7721, and HepG2 to investigate the role of ezrin in tumor cell growth and invasiveness.

Results

Our preliminary results showed that the expression of ezrin and γ-actin in MHCC-1, MHCC97-H, and SF7721 with higher metastatic potential were obviously up-regulated than those in SMMC7721, Hep3B, and HepG2 with lower potential. No different expression of β-actin was found in the above tumor cell lines. The outcome of RNAi indicated that decreasing ezrin expression can notably inhibit the proliferation of the four hepatocellular carcinoma cell lines (p < 0.01, n = 10). The proportion of cells in G2-M phase also decreased after RNAi. The number of pseudopods decreased as well after RNAi treatment (p < 0.01, n = 5). The mobility and invasiveness of cancer cells decreased with decreasing ezrin expression tested by transwell assay (p < 0.01, n = 8).

Conclusion

Ezrin plays an important role in the process of hepatocellular carcinoma cell proliferation, migration, and invasiveness.
Literatur
Zurück zum Zitat Andreoli C, Martin M, Le Borgne R, Reggio H, Mangeat P (1994). Ezrin has properties to self-associate at the plasma membrane. J Cell Sci 107(9):2509–2521PubMed Andreoli C, Martin M, Le Borgne R, Reggio H, Mangeat P (1994). Ezrin has properties to self-associate at the plasma membrane. J Cell Sci 107(9):2509–2521PubMed
Zurück zum Zitat Bretscher A, Edwards K, Fehon RG (2002) ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586–599PubMedCrossRef Bretscher A, Edwards K, Fehon RG (2002) ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586–599PubMedCrossRef
Zurück zum Zitat Chen ZC, Fadiel A, Feng YJ, Ohtani K, Rutherford T, Naftolin F (2001) Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1 alpha and epidermal growth factor. Cancer 92:3068–3075PubMedCrossRef Chen ZC, Fadiel A, Feng YJ, Ohtani K, Rutherford T, Naftolin F (2001) Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1 alpha and epidermal growth factor. Cancer 92:3068–3075PubMedCrossRef
Zurück zum Zitat Crepaldi T, Gautreau A, Comoglio PM, Louvard D, Arpin M (1997) Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cell. J Cell Biol 138(2):423–434PubMedCrossRef Crepaldi T, Gautreau A, Comoglio PM, Louvard D, Arpin M (1997) Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cell. J Cell Biol 138(2):423–434PubMedCrossRef
Zurück zum Zitat Harrision GM, Davies G, Martin TA (2002) Distribution and expression of CD44 isoforms and ezrin during prostate cancer–endothelium interaction. Int J Oncol 21:935–940 Harrision GM, Davies G, Martin TA (2002) Distribution and expression of CD44 isoforms and ezrin during prostate cancer–endothelium interaction. Int J Oncol 21:935–940
Zurück zum Zitat Hiscox S, Jiang WG (1999) Ezrin regulates cell–cell and cell–matrix adhesion: a possible role with E-cadherin/beta-catenin. J Cell Sci 112(18):3081–3090PubMed Hiscox S, Jiang WG (1999) Ezrin regulates cell–cell and cell–matrix adhesion: a possible role with E-cadherin/beta-catenin. J Cell Sci 112(18):3081–3090PubMed
Zurück zum Zitat Kaul SC, Mitsui Y, Komatsu Y, Reddel RR, Wadhwa R (1996) A highly expressed 81 kDa protein in immortalized mouse fibroblast: its proliferative function and identity with ezrin. Oncogene 13(6):1231–1237PubMed Kaul SC, Mitsui Y, Komatsu Y, Reddel RR, Wadhwa R (1996) A highly expressed 81 kDa protein in immortalized mouse fibroblast: its proliferative function and identity with ezrin. Oncogene 13(6):1231–1237PubMed
Zurück zum Zitat Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10(2):182–186PubMedCrossRef Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10(2):182–186PubMedCrossRef
Zurück zum Zitat Krieg J, Hunter T (1992) Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin. J Biol Chem 267:19258–19265PubMed Krieg J, Hunter T (1992) Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin. J Biol Chem 267:19258–19265PubMed
Zurück zum Zitat Lamb RF, Ozanne BW, Roy C, McGarry L, Stipp C, Mangeat P, Jay DG (1997) Essential functions of ezrin in maintenance of cell shape and lamellipodial extension in normal and transformed fibroblasts. Curr Biol 7(9):682–688PubMedCrossRef Lamb RF, Ozanne BW, Roy C, McGarry L, Stipp C, Mangeat P, Jay DG (1997) Essential functions of ezrin in maintenance of cell shape and lamellipodial extension in normal and transformed fibroblasts. Curr Biol 7(9):682–688PubMedCrossRef
Zurück zum Zitat Masahide T, Toshiro N, Yukihito S (2000) Altered expression of the ERM proteins in lung adenocarcinoma. US Can Acad Pathol 80(11):1643–1650 Masahide T, Toshiro N, Yukihito S (2000) Altered expression of the ERM proteins in lung adenocarcinoma. US Can Acad Pathol 80(11):1643–1650
Zurück zum Zitat Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, Tsukita S (1998) Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 140:647–657PubMedCrossRef Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, Tsukita S (1998) Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 140:647–657PubMedCrossRef
Zurück zum Zitat Nguyen R, Reczek D, Bretscher A (2001) Hierarchy of merlin and ezrin N and C-terminal domain interactions in homo and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J Biol Chem 276:7621–7629PubMedCrossRef Nguyen R, Reczek D, Bretscher A (2001) Hierarchy of merlin and ezrin N and C-terminal domain interactions in homo and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J Biol Chem 276:7621–7629PubMedCrossRef
Zurück zum Zitat Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F (1999) Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett 147(1/2):31–38PubMedCrossRef Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F (1999) Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett 147(1/2):31–38PubMedCrossRef
Zurück zum Zitat Pawlak G, Helfman DM (2000) Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 11(1):41–47CrossRef Pawlak G, Helfman DM (2000) Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 11(1):41–47CrossRef
Zurück zum Zitat Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, Lutchman M, Rouleau GA, Jaaskelainen J, Vaheri A, Carpen O (1997) Neurofibromatosis 2 tumour suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci 110:2249–2260PubMed Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, Lutchman M, Rouleau GA, Jaaskelainen J, Vaheri A, Carpen O (1997) Neurofibromatosis 2 tumour suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci 110:2249–2260PubMed
Zurück zum Zitat Shen ZY, Xu LY, Chen MH, Li EM, Li JT, Wu XY, Zeng Y, Xu LY, Chen MH, et al. (2003) Upregulated expression of ezrin and invasive phenotype in malignantly transformed esophageal epithelial cells. World J Gastroenterol 9(6):1182–1186PubMed Shen ZY, Xu LY, Chen MH, Li EM, Li JT, Wu XY, Zeng Y, Xu LY, Chen MH, et al. (2003) Upregulated expression of ezrin and invasive phenotype in malignantly transformed esophageal epithelial cells. World J Gastroenterol 9(6):1182–1186PubMed
Zurück zum Zitat Small JV (1994) Lamellipodia architecture: actin filament turnover and the lateral flow of actin filaments during motility. Semin Cell Biol 5:157–163PubMedCrossRef Small JV (1994) Lamellipodia architecture: actin filament turnover and the lateral flow of actin filaments during motility. Semin Cell Biol 5:157–163PubMedCrossRef
Zurück zum Zitat Small JV, Rottner K, Kaverina I, Anderson KI (1998) Assembling an actin cytoskeleton for cell attachment and movement. Biochim Biophys Acta 1404:271–281PubMedCrossRef Small JV, Rottner K, Kaverina I, Anderson KI (1998) Assembling an actin cytoskeleton for cell attachment and movement. Biochim Biophys Acta 1404:271–281PubMedCrossRef
Zurück zum Zitat Small JV, Stradal T, Vignal E, Rottner K (2002) The lamellipodium: where motility begins. Trends Cell Biol 12:112–120PubMedCrossRef Small JV, Stradal T, Vignal E, Rottner K (2002) The lamellipodium: where motility begins. Trends Cell Biol 12:112–120PubMedCrossRef
Zurück zum Zitat Tran Quang C, Gautreau A, Arpin M, Treisman R (2000) Ezrin function is required for ROCK-mediated fibroblast transformation by the net and dbl oncogenes. EMBO J 19:4565–4576PubMedCrossRef Tran Quang C, Gautreau A, Arpin M, Treisman R (2000) Ezrin function is required for ROCK-mediated fibroblast transformation by the net and dbl oncogenes. EMBO J 19:4565–4576PubMedCrossRef
Zurück zum Zitat Xie Q, Liu KD, Hu MY, Zhou K (2001) SF/HCF-c-met autocrine and paracrine promote metastasis in hepatocellular carcinoma. World J Gastroenterol 7:816–820PubMed Xie Q, Liu KD, Hu MY, Zhou K (2001) SF/HCF-c-met autocrine and paracrine promote metastasis in hepatocellular carcinoma. World J Gastroenterol 7:816–820PubMed
Zurück zum Zitat Yonemura S, Tsukita S, Tsukita S (1999) Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J Cell Biol 145(7):1497–1509PubMedCrossRef Yonemura S, Tsukita S, Tsukita S (1999) Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J Cell Biol 145(7):1497–1509PubMedCrossRef
Zurück zum Zitat Yonemura S, Matsui T, Tsukita S (2002) Rho-dependent and -independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J Cell Sci 115:2569–2580PubMed Yonemura S, Matsui T, Tsukita S (2002) Rho-dependent and -independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J Cell Sci 115:2569–2580PubMed
Zurück zum Zitat Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastasic regulators. Nat Med 10(2):175–181PubMedCrossRef Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastasic regulators. Nat Med 10(2):175–181PubMedCrossRef
Metadaten
Titel
The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness
verfasst von
Yan Zhang
Mei-Yu Hu
Wei-Zhong Wu
Zhi-Jun Wang
Kang Zhou
Xi-Liang Zha
Kang-Da Liu
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2006
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-006-0117-5

Weitere Artikel der Ausgabe 11/2006

Journal of Cancer Research and Clinical Oncology 11/2006 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.